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score (PS) and treatment effects estimated using conventional and
calendar time-speciﬁc PS (CTS-PS) approaches. Methods: A retrospec-
tive database analysis at a university-afﬁliated hospital in Thailand
was used. Diabetic patients receiving glucose-lowering medications
from July 2008 to June 2011 were included. Patients were categorized
into those exposed and not exposed to thiazolidinediones (TZDs). PSs
were estimated by using conventional PS and CTS-PS. In the CTS-PS,
PS was separately estimated for three speciﬁc calendar time periods.
Patients were matched 1:1 using caliper matching. The outcomes
were cardiovascular and all-cause hospitalizations. The TZD and non-
TZD groups were compared with Cox proportional hazard models.
Results: A total of 2165 patients were included. The average conven-
tional PS was 0.198 (95% conﬁdence interval [CI] 0.195–0.202), while
the average PS in the CTS-PS approach was 0.212 (0.206–0.218), 0.180
(0.173–0.188), and 0.205 (0.197–0.213) for July 2008 to June 2009, Julyee front matter Copyright & 2014, International S
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871), room 287, Chicago, IL 60612-7231, USA.2009 to June 2010, and July 2010 to June 2011, respectively. The average
difference in PS was 0.012 (P o 0.001), 0.009 (P r 0.002), and 0.000
(P ¼ 0.950) in the three calendar time periods. The adjusted hazard
ratios of the conventional PS-matched cohort were 0.97 (95% CI 0.39–
2.45) and 0.97 (95% CI 0.78–1.20) for CVD-related and all-cause
hospitalizations, while the adjusted hazard ratios of the CTS-PS–
matched cohort were 1.11 (95% CI 0.43–2.88) and 1.12 (95% CI
0.91–1.39), respectively. Conclusion: CTS-PS is different from PS esti-
mated by using the conventional approach. CTS-PS should be consid-
ered when a pattern of medication use has changed over the study
period.
Keywords: calendar time-speciﬁc propensity score, conventional
propensity score, diabetes mellitus, hospitalization, thiazolidinedione.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Propensity score (PS) is commonly used in observational studies
[1–9] for controlling confounding bias. Confounding bias is an
important and often encountered issue in observational studies.
The bias results from a confounder being related to both the
exposure of interest and the outcome and leads to a distortion in
the observed association between the exposure and the outcome.
In observational studies, there are many variables that can be
different between the exposed and unexposed groups and could
be potential confounders. PS is one method to try and account for
these differences between the two groups being compared.
Typically, the PS is estimated over the entire study time period.
The PS, which is the probability of being treated, is the estimated
probability of treatment received based on the effects ofcovariates averaged across all years included in the analysis. It
is quite possible, however, that the probability of treatment
receipt may change over the observation period. For example,
when clinical practice guidelines change or a new treatment is
launched, the probability of receiving a particular treatment may
change. Importantly, these changes in treatment may be related
to characteristics of patients that are also associated with the
outcome and therefore there is a change in the likelihood of a
confounder being present across the observation period. Ulti-
mately, these secular changes may result in calendar time acting
as a confounder or a strong predictor of treatment receipt.
A limited number of studies [10,11] have begun to point out
the limitations of conventional PS when estimating the treat-
ment effect over a long time frame. Two studies [10,11] used
calendar time-speciﬁc PS (CTS-PS), a method that takes intoociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
ystems, Outcomes and Policy, University of Illinois at Chicago, 833
V A L U E I N H E A L T H R E G I O N A L I S S U E S 3 C ( 2 0 1 4 ) 2 2 2 – 2 2 8 223account the change in the probability of receiving a particular
treatment over time for estimating PS, and determined the
effects of incorporating calendar time for the estimation of PS.
Brieﬂy, the conventional PS was estimated independent of when
patients were included, while the CTS-PS was estimated with
regard to the time that patients were included. The CTS-PS was
separately estimated by calendar time. Both studies found that
calendar time acted as a confounder and CTS-PS improved
confounding control. Thus, incorporating time when estimating
the PS might be important for future studies.
Because the studies were conducted in particular conditions,
however, it is not clear whether the results are generalizable to other
clinical conditions. Exploring the effects of calendar time on estimat-
ing PS across diseases and settings is important for determining the
generalizability of incorporating calendar time in estimating PS. To
evaluate the effect of incorporating calendar time on estimating PS,
this study was undertaken in the setting of the use of thiazolidine-
diones (TZDs) in diabetic patients. We used this scenario as our
evaluation of CTS-PS because a rosiglitazone safety issue, which may
increase the risk of myocardial infarction, was brought to the public
in late 2007. Awareness of this safety concern might lead to differ-
ences in the likelihood of receiving TZDs and might also be
associated with the risk for hospitalizations. We are utilizing data
beginning in the middle of 2008 in this study. Importantly, safety
warnings do not immediately affect prescribing patterns because
there is often a delay in response to safety concerns [12,13]. There-
fore, we believe that the setting and observational period for this
study are appropriate for comparing a conventional PS approach
with a CTS-PS approach.Fig. 1 – Illustration of conventional versus time-speciﬁc
propensity score estimations. Four example patients are
shown, each with different index dates. Patients 1 and 2
have index dates in period I while patient 3 had an index
date in period II and patient 4 had an index date in period III.
In the conventional PS estimation, all patients were included
in the same logistic regression to estimate PS (i.e., regardless
of the year of the index date). In the time-speciﬁc PS, patient
1 and patient 2 were included in the same regression to
estimate PS for each individual who was included in period
I. PS for patient 3 was estimated using logistic regression
among patients who were included in the study in period II,
while PS for patient 4 was estimated among patients
included in period III. PS, propensity score. Adapted from
Pharmacoepidemiol Drug Saf 2014;23:152–64 with
permission of John Wiley & Sons.Methods
Data Source
A retrospective cohort study was conducted using data from a
university-afﬁliated hospital in Thailand. This study was under-
taken with longitudinal patient-level databases including inpatient,
outpatient, and pharmacy databases that included data from
January 2008 to June 2012. Inpatient and outpatient databases
contained information on sex, health insurance, date of birth, date
of admission or visit, and diagnosis code (International Statistical
Classiﬁcation of Diseases, 10th revision [ICD-10]). Pharmacy databases
contained drug name, drug code, date of dispensing, regimen, and
amount of medication dispensed per prescription. The ethics
committee of the hospital approved this study.
Patients and Study Period
To be included in the study, patients had to have a diagnosis of
type 2 diabetes mellitus (ICD-10 codes E10.x, E11.x, E12.x, E13.x,
and E14.x) between July 2008 and June 2011 and have received
TZDs or other oral glucose-lowering agents. In addition, they
must have been at least 18 years old at the time of the diagnosis
to be included in the cohort. Patients requiring insulin therapy
within 6 months of the ﬁrst diagnosis were excluded in an
attempt to focus only on patients with type 2 diabetes mellitus.
The index date was the ﬁrst date the patient received TZDs or
other oral glucose-lowering agents after the diagnosis. Patients
were tracked from the index date to the end of June 2012. Patients
were classiﬁed into either the TZD group or the non-TZD
(comparator) group.
Outcome Measures
The outcomes of interest were cardiovascular disease (CVD)-
related and all-cause hospitalizations. CVD-related hospital-
ization was deﬁned as hospitalized patients with an ICD-10diagnosis code of I20.x–I25.x and I50.x, while all-cause hospital-
ization was deﬁned as any hospitalization during the follow-up
period.
PS Estimation
The conventional PS was estimated using logistic regression. The
model included 18 potential covariates that were considered to be
risk factors for outcomes and possibly related to physician’s
prescribing. The potential covariates included age, sex, health
insurance, comorbidities (hypertension, dyslipidemia, chronic kidney
disease, ischemic heart disease (IHD), chronic heart failure, and obesity)
and concurrent medications (aspirin, angiotensin-converting enzyme
inhibitors, angiotensin receptor blockers, alpha1-blockers, beta-blocker,
calcium channel blockers, digoxin, diuretics, lipid-lowering agents,
nitrate, and other hypertensive medications). All potential covariates
were identiﬁed in the 6-month period before the index date. We
used an automated model-ﬁtting process in which stepwise
forward selection with P o 0.2 as the inclusion criterion was
used to select covariates for inclusion in the model.
The estimation of CTS-PS was similar to the estimation of
conventional PS. Logistic regression was used to estimate the PS.
The CTS-PS estimation included 18 potential covariates within 6
months before the index date. We used an automated model-
ﬁtting process in which stepwise forward selection with
P o 0.2 as the inclusion criterion was used to select covariates
for inclusion in the model. The CTS-PS, however, was estimated
separately for each 1-year period of time in the observation
period. In this study, we separated the CTS-PS estimation into
three periods: July 2008 to June 2009, July 2009 to June 2010, and
July 2010 to June 2011. Individuals were included in time periods
on the basis of their index date, and the PS of each individual was
estimated within these time periods. In effect, three separate
logistic regressions for the estimation of the PS for each patient in
CTS-PS estimation were run. Individuals were included only in
the time period of their index date, whereas the index date was
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We compared conventional PS and CTS-PS in each time period
using percentage and absolute differences. The percentage differ-
ence was calculated as the difference between the conventional
PS and CTS-PS divided by the conventional PS, while the absolute
difference was the difference between the conventional PS and
CTS-PS. The paired t test was used to statistically compare the
two different approaches. We also calculated the percentages of
patients who had an absolute difference in the PS between the
two approaches above 0.1. We compared the odds ratios of each
covariate between conventional PS and CTS-PS approaches.
The Effects of TZDs on Hospitalizations
Similar methods in conventional PS and CTS-PS–matched cohorts
were applied to determine the association between TZDs and
hospitalization. Patients receiving TZDs were 1:1 matched to
patients not receiving TZDs by using both conventional PS and
CTS-PS. Empirical and theoretical research have demonstrated that
PS matching eliminates a greater proportion of baseline differences
between treated and untreated groups than does subclassiﬁcation
on the PS [14]. The caliper matching method with no replacement
[15,16] was used for both PS approaches. The caliper was 0.25  PS
SD. In the conventional PS approach, patients were matched to
controls regardless of the year of their index date, whereas in the
CTS-PS approach, patients were matched to controls only within
the time period of their index date.Table 1 – Baseline characteristics (full cohort).
Baseline characteristic Total (N ¼ 2165)
Age (y), mean  SD 58.8  12.7
Males, n (%) 963 (44.5)
Health insurance, n (%)
UC 1201 (55.5)
SSS 176 (8.1)
CSMBS 776 (35.8)
Others 10 (0.5)
Missing 2 (0.1)
Comorbidities, n (%)
Hypertension 1300 (60.1)
Dyslipidemia 1068 (49.3)
Chronic kidney disease 46 (2.1)
Ischemic heart disease 270 (12.5)
Chronic heart failure 90 (4.2)
Obesity 90 (4.2)
Concurrent medications, n (%)
Aspirin 957 (44.2)
ACEIs 786 (36.3)
ARBs 347 (16.0)
Alpha-blockers 96 (4.4)
Beta-blockers 422 (19.5)
CCBs 441 (20.4)
Diuretics 602 (27.8)
Digoxin 52 (2.4)
Lipid-lowering agents 1330 (61.4)
Antiplatelets 240 (11.1)
Nitrate 228 (10.5)
Other hypertensive medications 55 (2.5)
Follow-up time (days)
Mean  SD 1105.3  325.8
Median (IQR) 1104 (574)
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin rece
Medical Beneﬁt Scheme; IQR, interquartile range; SSS, Social Security ScAbsolute difference in mean or percentage was calculated to
evaluate the degree of balance between treated and untreated
groups for each baseline covariate in both conventional and
CTS-PS–matched cohorts. Cox proportional hazard models
were undertaken in both sets of analyses to examine the associa-
tion between receiving TZDs and outcomes. We compared adjusted
hazard ratios (HRs) with percentage and absolute differences.Results
A total of 15,807 patients diagnosed with diabetes mellitus were
identiﬁed. A total of 2,165 patients were included in the analysis.
Patients were on average aged 58.8  12.7 years, with 44.5% being
men. Most of them were insured under the Universal Coverage
health insurance scheme (55.5%) (Table 1). The number of
included patients having an index date was 761, 685, and 719
patients for July 2008 to June 2009, July 2009 to June 2010, and July
2010 to June 2011, respectively. Among the included patients, 430
(19.9%) patients received TZDs during the study period. Among
patients having the index date from July 2008 to June 2009, 161
(21.2%) patients received TZDs, while 124 (18.1%) and 145 (21.2%)
patients received TZDs among patients having the index date
from July 2009 to June 2010 and July 2010 to June 2011,
respectively.TZD (N ¼ 430) Non-TZD (N ¼ 1735)
56.1  12.6 59.5  12.7
212 (49.3) 751 (43.3)
182 (42.3) 1019 (58.7)
41 (9.5) 135 (7.8)
204 (47.4) 572 (33.0)
2 (0.5) 8 (0.5)
1 (0.2) 1 (0.1)
249 (57.9) 1051 (60.6)
230 (53.5) 838 (48.3)
3 (0.7) 43 (2.5)
32 (7.4) 238 (13.7)
14 (3.3) 76 (4.4)
27 (6.3) 63 (3.6)
179 (41.7) 778 (44.8)
136 (31.7) 650 (37.5)
92 (21.4) 255 (14.7)
17 (4.0) 79 (4.6)
86 (20.0) 336 (19.4)
65 (15.1) 376 (21.7)
111 (25.8) 491 (28.3)
10 (2.3) 42 (2.4)
272 (63.3) 1058 (61.0)
36 (8.4) 204 (11.8)
34 (7.9) 194 (11.2)
8 (1.9) 47 (2.7)
1122.8  327.5 1101.0  325.3
1139 (573) 1102 (583)
ptor blockers; CCBs, calcium channel blockers; CSMBS, Civil Servant
heme; TZD, thiazolidinedione; UC, Universal Coverage.
Table 2 – Odds ratio of covariates predicting PS.
Covariate Conventional
PS
CTS-PS
July 2008 to June
2009
July 2009 to June
2010
July 2010 to June
2011
Age 0.977 0.983 0.977 0.973
Male vs. female 0.842 0.885 0.905 0.735
Health insurance: CSMBS vs.
UC
1.858 1.545 2.365 1.827
Hypertension – – 0.550 –
Dyslipidemia 1.178 – 2.143 –
Ischemic heart disease 0.512 – 0.589 0.283
Chronic heart failure – – – 0.198
Chronic kidney disease 0.393 – – –
Obesity 1.492 1.866 – –
ARBs 1.585 2.061 – 1.408
Beta-blockers – – – 1.725
CCBs 0.610 0.688 – 0.405
Digoxin – 2.601 – –
Lipid-lowering agents – 1.445 0.676 –
ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; CSMBS, Civil Servant Medical Beneﬁt Scheme; CTS-PS; calendar time-
speciﬁc propensity score; PS, propensity score; UC, Universal Coverage.
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The factors associated with the receipt of TZDs changed over the
study period. The factors included in each of the PS models are
listed in Table 2. Based on the conventional PS estimation, the
probability of receiving TZDs inmen was less than that in women. It
was similar to the probability of receiving TZDs for each year based
on the CTS-PS approach. Similarly, the likelihood of receiving TZDs
in patients under the Civil Servant Medical Beneﬁt Scheme was
higher than that in patients under Universal Coverage in both
approaches. In the conventional PS approach, the likelihood of
receiving TZDs in patients with IHD was 0.512, but in the CTS-PS
approach, there was no association between receiving TZDs and IHD
in the period of July 2008 to June 2009. There were strong associa-
tions, however, between those in the periods of July 2009 to June
2010 and July 2010 to June 2011. Some predictors were not associated
with the receipt of TZDs in the conventional approach but they were
strong predictors of TZDs treatment in some years of the CTS-PS
approach. However, some predictors were associated with the
receipt of TZDs in the conventional approach but they were not
predictors of TZDs treatment in some years of the CTS-PS approach.
The details of associated predictors are presented in Table 2.Table 3 – Conventional PS and CTS-PS.
Time period Average PS
Conventional PS CTS-PS
July 2008 to June 09
(N ¼ 761)
0.200 (0.194–0.206) 0.212 (0.206–0.218)
July 2009 to June 2010
(N ¼ 683)
0.189 (0.183–0.196) 0.180 (0.173–0.188)
July 2010 to June 11
(N ¼ 718)
0.205 (0.199–0.212) 0.205 (0.197–0.213)
Overall (N ¼ 2162) 0.198 (0.195–0.202) NA
CTS-PS, calendar time-speciﬁc propensity score; NA, not applicable; PS,
* Paired t test.PS Estimation and Cohort Balance
The average conventional PS was 0.198, with 95% conﬁdence
interval (CI) ranging from 0.195 to 0.202. For the CTS-PS, the
average PS was 0.212, 0.180, and 0.205 for July 2008 to June 2009,
July 2009 to June 2010, and July 2010 to June 2011, respectively.
The difference in conventional PS and CTS-PS was 0.002, 0.009,
and 0.000 for July 2008 to June 2009, July 2009 to June 2010, and
July 2010 to June 2011, respectively. The difference for July 2008 to
June 2009, and July 2009 to June 2010, was statistically signiﬁcant
(P o 0.0001) (Table 3). The percentages of patients who had a
difference in PS between the two approaches of more than 0.1
was 4.71% for the full cohort, and 6.57%, 6.86%, and 0.70% for July
2008 to June 2009, July 2009 to June 2010, and July 2010 to June
2011, respectively. The distribution of conventional PS and CTS-
PS is shown in Fig. 2.
After PS matching, patients were classiﬁed into two cohorts as
conventional PS–matched cohort and CTS-PS–matched cohort.
The number of patients in the conventional PS–matched cohort
was 856 patients (428 patients in each group), while that in the
CTS-PS–matched cohort was 844 patients (422 patients in each
group). Baseline characteristics of both conventional PS–matchedAbsolute
difference
Percentage
difference
P* Number of patients
(%) who had
different PS
between two
approaches 40.1
0.012 6.00 o0.001 50 (6.57)
0.009 4.76 0.002 47 (6.86)
0.000 0.00 0.950 5 (0.70)
NA NA NA 102 (4.71)
propensity score.
Table 4 – Characteristics of the matched cohort.
Baseline characteristic Conventional PS ma
TZD (N ¼ 428) Non-T
Age (y), mean  SD 56.1  12.6 5
Males, n (%) 210 (49.1) 2
Health insurance, n (%)
UC 182 (42.5) 1
SSS 41(9.6)
CSMBS 203 (47.4) 2
Others 2 (0.5)
Missing –
Comorbidities, n (%)
Hypertension 248 (57.9) 2
Dyslipidemia 228 (53.3) 2
Chronic kidney disease 3 (0.7)
Ischemic heart disease 32 (7.5)
Chronic heart failure 14 (3.3)
Obesity 26 (6.1)
Concurrent medications
Aspirin 178 (41.6) 1
ACEIs 136 (31.8) 1
ARBs 91 (21.3)
Alpha-blockers 17 (4.0)
Beta-blockers 86 (20.1)
CCBs 65 (15.2)
Diuretics 110 (25.7) 1
Digoxin 10 (2.3)
Lipid-lowering agents 270 (63.1) 2
Antiplatelets 36 (8.4)
Nitrate 34 (8.0)
Other hypertensive medications 8 (1.9)
Follow-up time (d)
Mean  SD 927.5  338.0 88
Median (IQR) 942.0 (586.5) 87
ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin rece
Medical Beneﬁt Scheme; CTS-PS, calendar time-speciﬁc propensity scor
Scheme; TZD, thiazolidinedione; UC, Universal Coverage.
Fig. 2 – Distribution of propensity score by exposure.
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characteristics of exposed and unexposed groups of both cohorts
were well balanced.The Effects of TZDs on Hospitalizations
CVD-related and all-cause hospitalizations in patients receiving
TZDs were 2.1% and 41.4%. In the non-TZDs group, the percen-
tages of CVD-related and all-cause hospitalizations were 1.9%
and 37.2%. Based on the Cox proportional hazard model without
PS matching, the unadjusted HRs were 1.08 (95% CI 0.52–2.26) and
1.11 (95% CI 0.94–1.31) for CVD-related and all-cause hospital-
izations, respectively (Table 5).
The adjusted HRs of the conventional PS–matched cohort
were 0.97 (95% CI 0.39–2.45) and 0.97 (95% CI 0.78–1.20) for CVD-
related and all-cause hospitalizations, while the adjusted HRs
of the CTS-PS–matched cohort were 1.11 (95% CI 0.43–2.88) and
1.12 (95% CI 0.91–1.39) for CVD-related and all-cause hospital-
izations, respectively. The absolute differences of adjusted HRs
between CTS-PS and conventional PS were 0.14 and 0.15
for CVD-related and all-cause hospitalizations, respectively.
The percentages of differences were 14.43% and 15.46%,
respectively.tched CTS-PS matched
ZD (N ¼ 428) TZD (N ¼ 422) Non-TZD (N ¼ 422)
6.6  13.0 56.1  12.6 55.9  12.4
04 (47.7) 208 (49.3) 218 (51.7)
89 (44.2) 182 (43.1) 194 (45.9)
30 (7.0) 41 (9.7) 45 (10.7)
08 (48.6) 197 (46.7) 181 (42.9)
2 (0.5) 2 (0.5) 2 (0.5)
– – –
61 (61.0) 244 (57.8) 242 (57.4)
28 (53.3) 224 (53.1) 237 (56.2)
1 (0.2) 3 (0.7) 7 (1.6)
28 (6.5) 32 (7.5) 40 (9.5)
17 (4.0) 13 (3.1) 8 (1.9)
23 (5.4) 24 (5.7) 26 (6.2)
91 (44.7) 176 (41.7) 171 (40.5)
46 (34.1) 136 (32.2) 134 (31.8)
88 (20.6) 86 (20.4) 77 (18.3)
19 (4.4) 17 (4.0) 24 (5.7)
85 (19.9) 85 (20.1) 71 (16.8)
64 (15.0) 65 (15.4) 63 (14.9)
19 (27.8) 108 (25.6) 105 (24.9)
12 (2.8) 9 (2.1) 13 (3.1)
67 (62.4) 265 (62.8) 259 (61.4)
36 (8.4) 36 (8.5) 36 (8.5)
24 (5.6) 33 (7.8) 34 (8.1)
7 (1.7) 8 (1.9) 10 (2.4)
8.1  333.8 922.9  338.6 915.4  341.2
9.5 (606.0) 924.0 (585.0) 922.5 (657.0)
ptor blockers; CCBs, calcium channel blockers; CSMBS, Civil Servant
e; IQR, interquartile range; PS, propensity score; SSS, Social Security
Table 5 – Effects of TZDs on hospitalizations.
Outcomes Adjusted hazard ratio (95% conﬁdence interval) Differences between CTS-PS and
conventional PS
Unmatched
cohort
Conventional
PS
CTS-PS Absolute
difference
Percentage
difference*
CVD-related
hospitalization
1.08 (0.52–2.26) 0.97 (0.39–2.45) 1.11 (0.43–2.88) 0.14 14.43
All-cause hospitalization 1.11 (0.94–1.31) 0.97 (0.78–1.20) 1.12 (0.91–1.39) 0.15 15.46
CTS-PS, calendar time-speciﬁc propensity score; CVD, cardiovascular disease; PS, propensity score; TZD, thiazolidinedione.
* Percentage difference was calculated by using the following equation: % difference ¼ [(HRCTS-PS – HRconventional PS)/HRconventianal PS]  100.
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Our ﬁndings indicated that there is difference between PS
estimated by using the conventional PS and CTS-PS approaches.
CTS-PS is an appropriate option when researchers conduct a
study with a long study period and the probability of receiving
exposure changes overtime.
Previous studies have been conducted using a time-speciﬁc
approach to estimate PS [17,18]. The rationale was that the time-
speciﬁc approach was more ﬂexible and able to account for
changes in the way medications were used over time. For
example, Seeger et al. conducted a study to determine the effects
of statin on the occurrence of acute myocardial infarction. They
used the time-speciﬁc 6-month block to estimate PS for each
individual. They discussed that the time-speciﬁc approach
should be considered to estimate the PS for observational studies.
The study, however, did not compare the effect of time-speciﬁc
approach to other approaches.
To our knowledge, there are only two studies conducted to
compare the effects of CTS-PS with other approaches. The ﬁrst
study was conducted by Mack et al. [10,11]. The study aimed to
compare the effects of CTS-PS with conventional PS among
patients with stage III colon cancer who received oxaliplatin or
5-ﬂuorouracil. The authors found that the CST-PS approach could
balance baseline characteristics between treatment and control
groups better than the conventional approach. There was a
difference of about 22% in the HRs from the two approaches.
Another study was conducted by Dilokthornsakul et al. [10]. Their
ﬁndings were similar to Mack et al. [10,11], that the CST-PS
approach could balance baseline characteristics between treat-
ment and control groups better than the conventional approach.
The difference in the adjusted HRs from the two approaches was
much smaller and ranged from 2.7% to 5.3%. In our study, we also
found that the CST-PS approach could balance baseline charac-
teristics between treatment and control groups better than did
the conventional approach, which was similar to the previous
studies [10,11]. The relative differences of 14.4% to 15.6% in the
adjusted HRs from the two approaches, however, were observed.
The difference was similar to Mack et al.’s study [11] but a bit
different from Dilokthornsakul et al.’s study [10]. The absolute
differences were 0.14 to 0.15, which were relatively small and
might not be clinically signiﬁcant. Our objective was similar to
the previous studies but conducted in different clinical scenario
and setting.
The use of CTS-PS might be considered more appropriate
when there are changes in the patterns of medication use over
the study. For example, in our case study, there was new
information that using TZDs might increase risks of IHD during
the study period. It affected the likelihood of receipt of TZDs. The
odds ratio of receiving TZDs in patients with IHD changed overthe study time period. In this case, the use of CTS-PS might be
more suitable than the conventional PS approach, although the
adjusted HRs of CTS-PS and conventional PS approaches were not
much different. These indicated that CTS-PS is likely to be
appropriate for estimating PS in a situation of changing the
patterns of receiving exposure over the study period. An impor-
tant limitation of the use of CTS-PS in our study, however, is the
sample size. The beneﬁts of using CTS-PS may not be apparent
when the study has a small sample size in each calendar time
period, resulting in low statistical power for estimating PS.
Other limitations of this study should be noted. First, these
ﬁndings rely on a computerized hospital database. Like all
observational studies, there is the potential for misclassiﬁcation
of exposures, outcomes, and covariates. This has the potential to
affect both the propensity scores and the risk estimates derived
as part of this study. The hospital, however, uses these data for
reimbursement purposes, which may help to improve the
accuracy of the information. Moreover, there is no clear reason
why any misclassiﬁcation would be different between the
groups that we compared in this analysis. Second, some patients
seek medical care in other hospitals. This might affect the
estimates of hospitalization if not all events are captured. Again,
it is not clear that there would be differences between the groups
in terms of the complete capture of hospitalizations. Third, the
current study was conducted in only one university-afﬁliated
hospital with a particular condition. Patterns of physician
prescribing and probabilities of receiving treatment might be
different from other settings or other clinical conditions and
therefore the generalizability of our ﬁndings is limited. We feel,
however, that this work still provides another case study of the
effect that changes in prescribing patterns can have on PS
estimation.
In conclusion, we compared hospitalizations between those
receiving and not receiving TZD using different PS approaches
on a hospital database. We found that PS estimated by using
CTS-PS was different from PS estimated by using the conven-
tional approach. There is little effect, however, on treatment
estimates. It is important for researchers to consider CTS-PS
when a pattern of medication use has changed over the study
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